
What is claimed is:

1. A compound according to formula (I):



(I)

wherein:

R^1 and R^4 are each independently selected from the group consisting of hydrogen, $-NR^5R^6$, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkyl-C_1-C_{10}alkyl, C_5-C_8cycloalkenyl, C_5-C_8cycloalkenyl-C_1-C_{10}alkyl, C_3-C_8heterocycloalkyl, C_3-C_8heterocycloalkyl-C_1-C_{10}alkyl, aryl, aryl-C_1-C_{10}alkyl, heteroaryl and heteroaryl-C_1-C_{10}alkyl;

R^2 is $-NR^7R^8$ or $-OR^9$;

R^3 is H or C_1-C_4alkyl;

where R^5 and R^6 are each independently selected from the group consisting of hydrogen, C_1-C_{10}alkyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkyl-C_1-C_{10}alkyl, C_3-C_8heterocycloalkyl, C_3-C_8heterocycloalkyl-C_1-C_{10}alkyl, aryl, aryl-C_1-C_{10}alkyl, heteroaryl, heteroaryl-C_1-C_{10}alkyl, $-C(O)C_1$-C_4alkyl, $-C(O)C_3$-C_6cycloalkyl, $-C(O)C_3$-C_6heterocycloalkyl, -C(O)aryl, -C(O)heteroaryl and $-S(O)_2C_1$-C_4alkyl, or, when R^5 and R^6 are attached to the same nitrogen, R^5 and R^6 taken together with the nitrogen to which they are attached form a 5- or 6- or 7-membered saturated ring optionally containing one other heteroatom selected from oxygen, nitrogen and sulphur,

R^7 and R^8 are each independently selected from the group consisting of hydrogen, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, C_3-C_8cycloalkyl, C_3-C_8heterocycloalkyl, aryl and heteroaryl, and

R^9 is H or a cation, or C_1-C_{10}alkyl which is unsubstituted or substituted with one or more substituents independently selected from the group consisting of C_3-C_6cycloalkyl, heterocycloalkyl, aryl and heteroaryl;

X is O or S; and

Y is O or S;

where any carbon or heteroatom of R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9 is unsubstituted or is substituted with one or more substituents independently selected from C_1-C_6alkyl, C_1-C_6haloalkyl, halogen, $-OR^{10}$, $-NR^5R^6$, oxo, cyano, nitro, $-C(O)R^{10}$, $-C(O)OR^{10}$, $-SR^{10}$,

$-S(O)R^{10}$, $-S(O)_2R^{10}$, $-NR^5R^6$, $-CONR^5R^6$, $-N(R^5)C(O)R^{10}$, $-N(R^5)C(O)OR^{10}$, $-OC(O)NR^5R^6$, $-N(R^5)C(O)NR^5R^6$, $-SO_2NR^5R^6$, $-N(R^5)SO_2R^{10}$, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, aryl, C_1-C_6alkyl-aryl, heteroaryl and C_1-C_6alkyl-heteroaryl, wherein R^5 and R^6 are the same as defined above and R^{10} is selected from hydrogen, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, $-C(O)C_1$-C_4alkyl, -C(O)aryl, -C(O)heteroaryl, $-C(O)C_3$-C_6cycloalkyl, $-C(O)C_3$-C_6heterocycloalkyl, $-S(O)_2C_1$-C_4alkyl, C_3-C_8cycloalkyl, C_3-C_8heterocycloalkyl, C_6-C_{14}aryl, aryl-C_1-C_{10}alkyl, heteroaryl and heteroaryl-C_1-C_{10}alkyl;

and/or a pharmaceutically acceptable salt or solvate thereof.

2. A compound according to claim 1 wherein:

X is O;

Y is O;

R^1 and R^4 are each independently selected from the group consisting of hydrogen, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkyl-C_1-C_{10}alkyl, C_5-C_8cycloalkenyl, C_5-C_8cycloalkenyl-C_1-C_{10}alkyl, C_3-C_8heterocycloalkyl, C_3-C_8heterocycloalkyl-C_1-C_{10}alkyl, aryl, aryl-C_1-C_{10}alkyl, heteroaryl and heteroaryl-C_1-C_{10}alkyl;

R^2 is $-NR^7R^8$ or $-OR^9$;

R^3 is H or C_1-C_4alkyl;

where R^7 and R^8 are each independently selected from the group consisting of hydrogen, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, C_3-C_8cycloalkyl, C_3-C_8heterocycloalkyl, aryl and heteroaryl, and

R^9 is H or a cation, or C_1-C_{10}alkyl which is unsubstituted or substituted with one or more substituents independently selected from the group consisting of C_3-C_6cycloalkyl, heterocycloalkyl, aryl and heteroaryl,

where any carbon or heteroatom of R^1, R^2, R^3, R^4, R^7, R^8, R^9 is unsubstituted or is substituted with one or more substituents independently selected from C_1-C_6alkyl, C_1-C_6haloalkyl, halogen, $-OR^{10}$, $-NR^5R^6$, oxo, cyano, nitro, $-C(O)R^{10}$, $-C(O)OR^{10}$, $-SR^{10}$, $-S(O)R^{10}$, $-S(O)_2R^{10}$, $-NR^5R^6$, $-CONR^5R^6$, $-N(R^5)C(O)R^{10}$, $-N(R^5)C(O)OR^{10}$, $-OC(O)NR^5R^6$, $-N(R^5)C(O)NR^5R^6$, $-SO_2NR^5R^6$, $-N(R^5)SO_2R^{10}$, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, aryl, C_1-C_6alkyl-aryl, heteroaryl and C_1-C_6alkyl-heteroaryl, wherein R^5, and R^6 are as defined in claim 1 and R^{10} is selected from hydrogen, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, $-C(O)C_1$-C_4 alkyl, -C(O)aryl, -C(O)heteroaryl, $-C(O)C_3$-C_6cycloalkyl, $-C(O)C_3$-C_6heterocycloalkyl, $-S(O)_2C_1$-C_4 alkyl, C_3-C_8cycloalkyl, C_3-C_8heterocycloalkyl, C_6-C_{14}aryl, aryl-C_1-C_{10}alkyl, heteroaryl and heteroaryl-C_1-C_{10}alkyl;

and/or a pharmaceutically acceptable salt or solvate thereof.

3. A compound according to claim 1 wherein:

X is O;

Y is O;

R^1 and R^4 are each independently selected from the group consisting of hydrogen, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkyl-C_1-C_{10}alkyl, C_5-C_8cycloalkenyl, C_5-C_8cycloalkenyl-C_1-C_{10}alkyl, C_3-C_8heterocycloalkyl, C_3-C_8heterocycloalkyl-C_1-C_{10}alkyl, aryl, aryl-C_1-C_{10}alkyl, heteroaryl and heteroaryl-C_1-C_{10}alkyl;

R^2 is $-OR^9$;

R^3 is H or C_1-C_4alkyl;

R^9 is H or a cation, or C_1-C_{10}alkyl which is unsubstituted or is substituted with one or more substituents independently selected from the group consisting of C_3-C_6 cycloalkyl, heterocycloalkyl, aryl and heteroaryl,

where any carbon or heteroatom of R^1, R^2, R^3, R^4, R^9 is unsubstituted or is substituted with one or more substituents independently selected from C_1-C_6alkyl, C_1-C_6haloalkyl, halogen, $-OR^{10}$, $-NR^5R^6$, oxo, cyano, nitro, $-C(O)R^{10}$, $-C(O)OR^{10}$, $-SR^{10}$, $-S(O)R^{10}$, $-S(O)_2R^{10}$, $-NR^5R^6$, $-CONR^5R^6$, $-N(R^5)C(O)R^{10}$, $-N(R^5)C(O)OR^{10}$, $-OC(O)NR^5R^6$, $-N(R^5)C(O)NR^5R^6$, $-SO_2NR^5R^6$, $-N(R^5)SO_2R^{10}$, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, aryl, C_1-C_6alkyl-aryl, heteroaryl and C_1-C_6 alkyl-heteroaryl, wherein R^5, and R^6 are the same as defined in claim 1 and R^{10} is selected from hydrogen, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, $-C(O)C_1$-C_4alkyl, -C(O)aryl, -C(O)heteroaryl, $-C(O)C_3$-C_6cycloalkyl, $-C(O)C_3$-C_6heterocycloalkyl, $-S(O)_2C_1$-C_4alkyl, C_3-C_8cycloalkyl, C_3-C_8heterocycloalkyl, C_6-C_{14}aryl, aryl-C_1-C_{10}alkyl, heteroaryl and heteroaryl-C_1-C_{10}alkyl; and/or a pharmaceutically acceptable salt or solvate thereof.

4. A compound according to claim 1 wherein:

X is O;

Y is O;

R^1 and R^4 are each independently selected from the group consisting of hydrogen, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkyl-C_1-C_{10}alkyl, C_5-C_8cycloalkenyl, C_5-C_8cycloalkenyl-C_1-C_{10}alkyl, C_3-C_8heterocycloalkyl, C_3-C_8heterocycloalkyl-C_1-C_{10}alkyl, aryl, aryl-C_1-C_{10}alkyl, heteroaryl and heteroaryl-C_1-C_{10}alkyl;

R^2 is $-OR^9$;

R^3 is H;

R^9 is H or a cation;

where any carbon or heteroatom of R^1, R^2, R^3, R^4 is unsubstituted or is substituted with one or more substituents independently selected from C_1-C_6alkyl, C_1-C_6haloalkyl, halogen, -OR^{10}, -NR^5R^6, oxo, cyano, nitro, -$C(O)R^{10}$, -$C(O)OR^{10}$, -SR^{10}, -$S(O)R^{10}$, -$S(O)_2R^{10}$, -NR^5R^6, -$CONR^5R^6$, -$N(R^5)C(O)R^{10}$, -$N(R^5)C(O)OR^{10}$, -$OC(O)NR^5R^6$, -$N(R^5)C(O)NR^5R^6$, -$SO_2NR^5R^6$, -$N(R^5)SO_2R^{10}$, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, aryl, C_1-C_6alkyl-aryl, heteroaryl and C_1-C_6 alkyl-heteroaryl, wherein R^5, and R^6 are the same as defined in claim 1 and R^{10} is selected from hydrogen, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, -$C(O)C_1$-C_4alkyl, -C(O)aryl, -C(O)heteroaryl, -$C(O)C_3$-C_6cycloalkyl, -$C(O)C_3$-C_6heterocycloalkyl, -$S(O)_2C_1$-C_4 alkyl, C_3-C_8 cycloalkyl, C_3-C_8heterocycloalkyl, C_6-C_{14} aryl, aryl-C_1-C_{10}alkyl, heteroaryl and heteroaryl-C_1-C_{10}alkyl; and/or a pharmaceutically acceptable salt or solvate thereof.

5. A compound according to claim 1 which is selected from:

N-{[1-(4-chlorophenyl)-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[1-{[2,4-bis(methyloxy)phenyl]methyl}-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[1-(4-chlorophenyl)-6-hydroxy-4-oxo-3-(phenylmethyl)-2-thioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-({6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-{[6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[6-hydroxy-2,4-dioxo-1-phenyl-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine; and

N-[(1-(1,1-dimethylethyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

and/or a pharmaceutically acceptable salt or solvate thereof.

6. A compound according to claim 1 which is selected from:

N-{[6-Hydroxy-2,4-dioxo-3-(phenylmethyl)-1-(2-pyridinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[6-Hydroxy-1-(2-nitrophenyl)-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[1-[(3-Cyanophenyl)methyl]-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-[(6-Hydroxy-2,4-dioxo-3-(phenylmethyl)-1-{[4-(trifluoromethyl)phenyl]methyl}-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[1-[(3,4-Dichlorophenyl)methyl]-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[6-Hydroxy-1-{[3-(methyloxy)phenyl]methyl}-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[1-[(2,6-Dichlorophenyl)methyl]-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[6-Hydroxy-1-methyl-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[1-Cyclohexyl-3-(2-cyclopropylethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-[(1,3-Dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[1-Hexyl-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[1-Ethyl-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[6-Hydroxy-2,4-dioxo-3-(phenylmethyl)-1-propyl-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[1-Butyl-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[6-Hydroxy-2,4-dioxo-1-(2-phenylethyl)-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[3-{[4-(1,1-Dimethylethyl)phenyl]methyl}-6-hydroxy-1-(1-methylethyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-[(1-cyclohexyl-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[6-Hydroxy-1,3-bis(1-methylethyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[3-[(2-Bromophenyl)methyl]-1-(1,1-dimethylethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-[(1-(2,6-Dichlorophenyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(1-(2,4-dichlorophenyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(1-(2-Bromophenyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(1-(2-Biphenylyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[6-Hydroxy-2,4-dioxo-3-(phenylmethyl)-1-(tetrahydro-2*H*-pyran-4-yl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-(tetrahydro-2*H*-pyran-4-yl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[3-{[4-(1,1-Dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1-(2-thienyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-({1-Cyclohexyl-6-hydroxy-3-[3-(4-morpholinyl)propyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-{[3-{[4-(1,1-Dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1-(3-pyridinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-({1-Cyclohexyl-3-[(2-fluorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({3-[(2-Chlorophenyl)methyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({1-Cyclohexyl-3-[(2,4-dimethylphenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-[(2,4,6-trifluorophenyl)methyl]-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[(1-Cyclohexyl-6-hydroxy-3-{[4-(1-methylethyl)phenyl]methyl}-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-({1-Cyclohexyl-3-[(2-ethylphenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({1-Cyclohexyl-3-[(4-ethylphenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-[(2,4,6-trimethylphenyl)methyl]-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-{[1-Cyclohexyl-3-(2-cyclohexylethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-[(3-{[3,5-Bis(methyloxy)phenyl]methyl}-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[1-Cyclohexyl-6-hydroxy-3-(2-naphthalenylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-({1-Cyclohexyl-6-hydroxy-3-[(4-methylphenyl)methyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-{[3-(4-Biphenylylmethyl)-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-[(3-{[4-(1,3-Benzoxazol-2-yl)phenyl]methyl}-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-({3-[2-(4-Biphenylyl)-2-oxoethyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[(1,3-Bis{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[1-Cyclohexyl-6-hydroxy-3-(4-methylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-({1-Cyclohexyl-3-[4-(1,1-dimethylethyl)cyclohexyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[(1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-({1-Cyclohexyl-3-[4-(1,1-dimethylethyl)phenyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-{[1-Cyclohexyl-3-(cyclohexylmethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-[(3-Cycloheptyl-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-tricyclo[3.3.1.1^{3,7}]dec-1-yl-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-({1-[(1*R*,2*R*,4*S*)-Bicyclo[2.2.1]hept-2-yl]-3-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-{[1-Cyclohexyl-6-hydroxy-3-(3-methylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-[(3-Cyclohexyl-1-cyclopropyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(1-Cyclobutyl-3-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(3-Cyclohexyl-1-cyclopentyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[6-Hydroxy-1,3-bis(3-methylbutyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-[(6-Hydroxy-1,3-bis{[2-(methyloxy)phenyl]methyl}-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-({1,3-Bis[(2-chlorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[(1,3-Dihexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[1-Cyclohexyl-6-hydroxy-3-(2-methylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[1-Cyclohexyl-6-hydroxy-3-(2-naphthalenyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-[(1-Cyclohexyl-3-hexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(1,3-Dicycloheptyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(1,3-Dicyclopentyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[1-Cyclohexyl-3-(2,3-dimethylcyclohexyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

4-[5-{[(Carboxymethyl)amino]carbonyl}-3-cyclohexyl-4-hydroxy-2,6-dioxo-3,6-dihydro-1(2*H*)-pyrimidinyl]cyclohexanecarboxylic acid;

N-{[1-Cyclohexyl-3-(4-ethylcyclohexyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

cis-4-[3-Cyclohexyl-5-({[2-(ethyloxy)-2-oxoethyl]amino}carbonyl)-4-hydroxy-2,6-dioxo-3,6-dihydro-1(2*H*)-pyrimidinyl]cyclohexanecarboxylic acid;

N-{[1-Cyclohexyl-6-hydroxy-3-(1-methylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

3-[5-{[(Carboxymethyl)amino]carbonyl}-3-cyclohexyl-4-hydroxy-2,6-dioxo-3,6-dihydro-1(2H)-pyrimidinyl]cyclohexanecarboxylic acid;

N-{[1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-(2-oxo-2-phenylethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-[(1-Cyclohexyl-6-hydroxy-3-{2-[4-(methyloxy)phenyl]-2-oxoethyl}-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-({1-Cyclohexyl-6-hydroxy-3-[2-(4-methylphenyl)-2-oxoethyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-{[1-Cyclohexyl-3-(3,3-dimethyl-2-oxobutyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-({1-Cyclohexyl-3-[2-(4-fluorophenyl)-2-oxoethyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({3-[2-(4-Cyanophenyl)-2-oxoethyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({3-[2-(1-Benzofuran-2-yl)-2-oxoethyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-{[3-Cyclohexyl-6-hydroxy-1-(1-naphthalenyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[3-Cyclohexyl-1-(4,4-dimethylcyclohexyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-({1-Cyclohexyl-3-[(2,3-difluorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

Ethyl *N*-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonothioyl]glycinate;

N-[(1,3-Dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonothioyl]glycine;

6-[5-{[(Carboxymethyl)amino]carbonyl}-3-cyclohexyl-6-hydroxy-2,4-dioxo-3,4-dihydro-1(2*H*)-pyrimidinyl]hexanoic acid;

6-[5-{[(Carboxymethyl)amino]carbonothioyl}-3-cyclohexyl-6-hydroxy-2,4-dioxo-3,4-dihydro-1(2*H*)-pyrimidinyl]hexanoic acid;

N-({1-Cyclohexyl-3-[(3,4-dichlorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[(1-Cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-({3-Cyclohexyl-6-hydroxy-1-[*trans*-4-(methyloxy)cyclohexyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({1-[1,1'-Bi(cyclohexyl)-4-yl]-3-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-{[6-Hydroxy-2,4-dioxo-1,3-bis(1-propylbutyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-({3-(2-Cyclopropylethyl)-6-hydroxy-1-[3-(methyloxy)phenyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-{[3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-(4-phenylcyclohexyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-({1-Cyclohexyl-3-[(3,4-difluorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({3-(2-Cyclopropylethyl)-6-hydroxy-1-[4-(methyloxy)phenyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-{[3-(2-Cyclopropylethyl)-6-hydroxy-1-(3-nitrophenyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-({3-(2-Cyclopropylethyl)-6-hydroxy-2,4-dioxo-1-[4-(2-thienyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-{[1,3-Bis(1-ethylpropyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-[(6-Hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(1-Cyclohexyl-6-hydroxy-2,4-dioxo-3-{[4-(trifluoromethyl)phenyl]methyl}-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(1,3-Dibutyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[1,3-Bis(2-cyclopropylethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[6-Hydroxy-1,3-bis(2-methylpropyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-({3-(2-Cyclopropylethyl)-6-hydroxy-1-[3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({3-(2-Cyclopropylethyl)-6-hydroxy-1-[4-(2-methyl-1,3-thiazol-4-yl)phenyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-{[3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-(4-piperidinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-({3-(2-Cyclopropylethyl)-1-[4-(2-furanyl)phenyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-{[1,3-Bis(1,1-dimethylpropyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-(3-piperidinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[3-Cyclohexyl-6-hydroxy-2,4-dioxo-1-(1-{[(phenylmethyl)oxy]carbonyl}-3-piperidinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[1-(1-Acetyl-3-piperidinyl)-3-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-[(1-Cyclohexyl-3-{[4-fluoro-2-(trifluoromethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-({3-[(2-Bromophenyl)methyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({1-Cyclohexyl-3-[(2,6-dichlorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[(3-{[2-Bromo-5-(methyloxy)phenyl]methyl}-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(3-{[2,4-Bis(trifluoromethyl)phenyl]methyl}-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-({3-[(2-Bromo-5-fluorophenyl)methyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[(3-{[2-Bromo-4-(1,1-dimethylethyl)phenyl]methyl}-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-({1-Cyclohexyl-6-hydroxy-3-[(2-methylphenyl)methyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-{[1-Cyclohexyl-3-(1,1-dimethylpropyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine; and

N-{[1,3-Bis(2,6-dichlorophenyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

and/or a pharmaceutically acceptable salt or solvate thereof.

7. A pharmaceutical composition which comprises a compound as described in claim 1 and one or more of pharmaceutically acceptable carriers, diluents and excipients.

8. A use of a compound as described in claim 1 in the preparation of the medicament for treating anemia in a mammal.

9. The use of claim 8 wherein the mammal is a human.

10. A use of a compound as described in claim 1 in the preparation of a medicament for inhibiting HIF prolyl hydroxylases in a mammal.

11. The use of claim 10 wherein the mammal is a human.

12. A use of a compound as described in claim 1 in the preparation of a medicament for treating Ischemia in a mammal.

13. The use of claim 12 wherein the mammal is a human.

14. A use of a compound as described in claim 1 in the preparation of a medicament for treating myocardial infarction in a mammal.

15. The use of claim 14 wherein the mammal is a human.

16. A use of a) a compound as described in claim 1; and b) EPO or a derivative thereof, in the preparation of a medicament for treating diseases of the hematopoietic system.

17. A compound as described in claim 1 for use in treating anemia in a mammal.

18. The compound of claim 17 wherein the mammal is a human.

19. A compound as described in claim 1 for use in inhibiting HIF prolyl hydroxylases in a mammal.

20. The compound of claim 19 wherein the mammal is a human.

21. A compound as described in claim 1 for use in treating Ischemia in a mammal.

22. The compound of claim 21 wherein the mammal is a human.


23. A compound as described in claim 1 for use in treating myocardial infarction in a mammal.

24. The compound of claim 23 wherein the mammal is a human.

25. A compound as described in claim 1 and EPO or a derivative thereof, for use in treating diseases of the hematopoietic system.

26. A process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent and an effective amount of a compound as described in claim 1 which process comprises bringing the compound as described in claim 1 into association with a pharmaceutically acceptable carrier or diluent.

27. A process for preparing a compound of formula (I)



(I)

wherein:

R^1 and R^4 are each independently selected from the group consisting of hydrogen, $-NR^5R^6$, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkyl-C_1-C_{10}alkyl, C_5-C_8cycloalkenyl, C_5-C_8cycloalkenyl-C_1-C_{10}alkyl, C_3-C_8heterocycloalkyl, C_3-C_8heterocycloalkyl-C_1-C_{10}alkyl, aryl, aryl-C_1-C_{10}alkyl, heteroaryl and heteroaryl-C_1-C_{10}alkyl;

R^2 is $-NR^7R^8$ or $-OR^9$;

R^3 is H or C_1-C_4alkyl;

where R^5 and R^6 are each independently selected from the group consisting of hydrogen, C_1-C_{10}alkyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkyl-C_1-C_{10}alkyl, C_3-C_8heterocycloalkyl, C_3-C_8heterocycloalkyl-C_1-C_{10}alkyl, aryl, aryl-C_1-C_{10}alkyl, heteroaryl, heteroaryl-C_1-C_{10}alkyl, $-CO(C_1$-C_4alkyl), $-CO(C_3$-C_6cycloalkyl), $-CO(C_3$-C_6heterocycloalkyl), -CO(aryl), -CO(heteroaryl) and $-SO_2(C_1$-C_4alkyl), or, when R^5 and R^6 are attached to the same nitrogen, R^5 and R^6 taken together with the nitrogen to which they are attached form a 5- or 6- or 7-membered saturated ring optionally containing one other heteroatom selected from oxygen, nitrogen and sulphur,

R^7 and R^8 are each independently selected from the group consisting of hydrogen, C_1-C_{10}alkyl, C_2-C_{10} alkenyl, C_2-C_{10}alkynyl, C_3-C_8cycloalkyl, C_3-C_8heterocycloalkyl, aryl and heteroaryl, and


R^9 is H or a cation, or C_1-C_{10}alkyl which is unsubstituted or substituted with one or more substituents independently selected from the group consisting of C_3-C_6cycloalkyl, heterocycloalkyl, aryl and heteroaryl;

X is O or S; and

Y is O or S;

where any carbon or heteroatom of R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9 is unsubstituted or is substituted with one or more substituents independently selected from C_1-C_6alkyl, C_1-C_6haloalkyl, halogen, $-OR^{10}$, $-NR^5R^6$, oxo, cyano, nitro, $-C(O)R^{10}$, $-C(O)OR^{10}$, $-SR^{10}$, $-S(O)R^{10}$, $-S(O)_2R^{10}$, $-NR^5R^6$, $-CONR^5R^6$, $-N(R^5)C(O)R^{10}$, $-N(R^5)C(O)OR^{10}$, $-OC(O)NR^5R^6$, $-N(R^5)C(O)NR^5R^6$, $-SO_2NR^5R^6$, $-N(R^5)SO_2R^{10}$, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, aryl, C_1-C_6alkyl-aryl, heteroaryl and C_1-C_6alkyl-heteroaryl, wherein R^5 and R^6 are the same as defined above and R^{10} is selected from hydrogen, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, $-CO(C_1$-C_4alkyl), -CO(aryl), -CO(heteroaryl), $-CO(C_3$-C_6cycloalkyl), $-CO(C_3$-C_6heterocycloalkyl), $-SO_2(C_1$-C_4alkyl), C_3-C_8cycloalkyl, C_3-C_8heterocycloalkyl, C_6-C_{14}aryl, aryl-C_1-C_{10}alkyl, heteroaryl and heteroaryl-C_1-C_{10}alkyl;


comprising treating a compound of formula A:



A

wherein R^1 and R^4 are the same as for those groups in formula (I) with glycine and an appropriate base in an appropriate solvent under conventional thermal conditions or by microwave irradiation, to form the compound of formula (I).

28. A process for preparing a compound of formula (I)



(I)

wherein:

R^1 and R^4 are each independently selected from the group consisting of hydrogen, $-NR^5R^6$, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkyl-C_1-C_{10}alkyl, C_5-C_8cycloalkenyl, C_5-C_8cycloalkenyl-C_1-C_{10}alkyl, C_3-C_8heterocycloalkyl, C_3-C_8heterocycloalkyl-C_1-C_{10}alkyl, aryl, aryl-C_1-C_{10}alkyl, heteroaryl and heteroaryl-C_1-C_{10}alkyl;

R^2 is $-NR^7R^8$ or $-OR^9$;

R^3 is H or C_1-C_4alkyl;

where R^5 and R^6 are each independently selected from the group consisting of hydrogen, C_1-C_{10}alkyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkyl-C_1-C_{10}alkyl, C_3-C_8heterocycloalkyl, C_3-C_8heterocycloalkyl-C_1-C_{10}alkyl, aryl, aryl-C_1-C_{10}alkyl, heteroaryl, heteroaryl-C_1-C_{10}alkyl, $-CO(C_1$-C_4alkyl), $-CO(C_3$-C_6cycloalkyl), $-CO(C_3$-C_6heterocycloalkyl), -CO(aryl), -CO(heteroaryl) and $-SO_2(C_1$-C_4alkyl), or, when R^5 and R^6 are attached to the same nitrogen, R^5 and R^6 taken together with the nitrogen to which they are attached form a 5- or 6- or 7-membered saturated ring optionally containing one other heteroatom selected from oxygen, nitrogen and sulphur,

R^7 and R^8 are each independently selected from the group consisting of hydrogen, C_1-C_{10}alkyl, C_2-C_{10} alkenyl, C_2-C_{10}alkynyl, C_3-C_8cycloalkyl, C_3-C_8heterocycloalkyl, aryl and heteroaryl, and


R^9 is H or a cation, or C_1-C_{10}alkyl which is unsubstituted or substituted with one or more substituents independently selected from the group consisting of C_3-C_6cycloalkyl, heterocycloalkyl, aryl and heteroaryl;

X is O or S; and

Y is O or S;

where any carbon or heteroatom of R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9 is unsubstituted or is substituted with one or more substituents independently selected from C_1-C_6alkyl, C_1-C_6haloalkyl, halogen, $-OR^{10}$, $-NR^5R^6$, oxo, cyano, nitro, $-C(O)R^{10}$, $-C(O)OR^{10}$, $-SR^{10}$, $-S(O)R^{10}$, $-S(O)_2R^{10}$, $-NR^5R^6$, $-CONR^5R^6$, $-N(R^5)C(O)R^{10}$, $-N(R^5)C(O)OR^{10}$, $-OC(O)NR^5R^6$, $-N(R^5)C(O)NR^5R^6$, $-SO_2NR^5R^6$, $-N(R^5)SO_2R^{10}$, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, aryl, C_1-C_6alkyl-aryl, heteroaryl and C_1-C_6alkyl-heteroaryl, wherein R^5 and R^6 are the same as defined above and R^{10} is selected from hydrogen, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, $-CO(C_1$-C_4alkyl), -CO(aryl), -CO(heteroaryl), $-CO(C_3$-C_6cycloalkyl), $-CO(C_3$-C_6heterocycloalkyl), $-SO_2(C_1$-C_4alkyl), C_3-C_8cycloalkyl, C_3-C_8heterocycloalkyl, C_6-C_{14}aryl, aryl-C_1-C_{10}alkyl, heteroaryl and heteroaryl-C_1-C_{10}alkyl;

comprising treating a compound of formula B:




B

wherein R^1 and R^4 are the same as for those groups in formula (I) with an alkali, in an appropriate solvent at a suitable temperature to form the compound of formula (I).

What is claimed is:

1. A compound according to formula (I):



(I)

wherein:

R^1 and R^4 are each independently selected from the group consisting of hydrogen, —NR^5R^6, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkyl-C_1-C_{10}alkyl, C_5-C_8cycloalkenyl, C_5-C_8cycloalkenyl-C_1-C_{10}alkyl, C3-C8heterocycloalkyl, C_3-C_8heterocycloalkyl-C_1-C_{10}alkyl, aryl, aryl-C_1-C_{10}alkyl, heteroaryl and heteroaryl-C_1-C_{10}alkyl;

R^2 is —NR^7R^8 or —OR^9;

R^3 is H or C_1-C_4alkyl;

where R^5 and R^6 are each independently selected from the group consisting of hydrogen, C_1-C_{10}alkyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkyl-C_1-C_{10}alkyl, C_3-C_8heterocycloalkyl, C_3-C_8heterocycloalkyl-C_1-C_{10}alkyl, aryl, aryl-C_1-C_{10}alkyl, heteroaryl, heteroaryl-C_1-C_{10}alkyl, —$C(O)C_1$-C_4alkyl, —$C(O)C_3$-C_6cycloalkyl, —$C(O)C_3$-C_6heterocycloalkyl, —C(O)aryl, —C(O)heteroaryl and —$S(O)_2C_1$-C_4alkyl, or, when R^5 and R^6 are attached to the same

nitrogen, R^5 and R^6 taken together with the nitrogen to which they are attached form a 5- or 6- or 7-membered saturated ring optionally containing one other heteroatom selected from oxygen, nitrogen and sulphur,

R^7 and R^8 are each independently selected from the group consisting of hydrogen, C_1-C_{10}alkyl, C_2-C_{10} alkenyl, C_2-C_{10}alkynyl, C_3-C_8cycloalkyl, C_3-C_8heterocycloalkyl, aryl and heteroaryl, and

R^9 is H or a cation, or C_1-C_{10}alkyl which is unsubstituted or substituted with one or more substituents independently selected from the group consisting of C_3-C_6cycloalkyl, heterocycloalkyl, aryl and heteroaryl;

X is O or S; and

Y is O or S;

where any carbon or heteroatom of R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9 is unsubstituted or is substituted with one or more substituents independently selected from C_1-C_6alkyl, C_1-C_6haloalkyl, halogen, —OR^{10}, —NR^5R^6, oxo, cyano, nitro, —$C(O)R^{10}$, —$C(O)OR^{10}$, —SR^{10}, —$S(O)R^{10}$, —$S(O)_2R^{10}$, —NR^5R^6, —$CONR^5R^6$, —$N(R^5)C(O)R^{10}$, —$N(R^5)C(O)OR^{10}$, —$OC(O)NR^5R^6$, —$N(R^5)C(O)NR^5R^6$, —$SO_2NR^5R^6$, —$N(R^5)SO_2R^{10}$, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, aryl, C_1-C_6alkyl-aryl, heteroaryl and C_1-C_6alkyl-heteroaryl, wherein R^5 and R^6 are the same as defined above and $R^{10}$is selected from hydrogen, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, —$C(O)C_1$-C_4alkyl, —C(O)aryl, —C(O)heteroaryl, —$C(O)C_3$-C_6cycloalkyl, —C(O) C_3-C_6heterocycloalkyl, —$S(O)_2C_1$-C_4alkyl,

C_3-C_8cycloalkyl, C_3-C_8heterocycloalkyl, C_6-C_{14}aryl, aryl-C_1-C_{10}alkyl, heteroaryl and heteroaryl-C_1-C_{10}alkyl;

or a pharmaceutically acceptable salt thereof.

2. A compound according to claim **1** wherein:

X is O;

Y is O;

R^1 and R^4 are each independently selected from the group consisting of hydrogen, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkyl-C_1-C_{10}alkyl, C_5-C_8cycloalkenyl, C_5-C_8cycloalkenyl-C_1-C_{10}alkyl, C_3-C_8heterocycloalkyl, C3-C8heterocycloalkyl-C_1-C_{10}alkyl, aryl, aryl-C_1-C_{10}alkyl, heteroaryl and heteroaryl-C_1-C_{10}alkyl;

R^2 is —NR^7R^8 or —OR^9;

R^3 is H or C_1-C_4alkyl;

where R^7 and R^8 are each independently selected from the group consisting of hydrogen, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, C_3-C_8cycloalkyl, C_3-C_8heterocycloalkyl, aryl and heteroaryl, and

R^9 is H or a cation, or C_1-C_{10}alkyl which is unsubstituted or substituted with one or more substituents independently selected from the group consisting of C_3-C_6cycloalkyl, heterocycloalkyl, aryl and heteroaryl,

where any carbon or heteroatom of R^1, R^2, R^3, R^4, R^7, R^8, R^9 is unsubstituted or is substituted with one or more substituents independently selected from C_1-C_6alkyl, C_1-C_6haloalkyl, halogen, —OR^{10}, —NR^5R^6, oxo, cyano, nitro, —$C(O)R^{10}$, —$C(O)OR^{10}$, —SR^{10}, —$S(O)R^{10}$, —$S(O)_2R^{10}$, —NR^5R^6, —$CONR^5R^6$, —$N(R^5)C(O)R^{10}$, —$N(R^6)C(O)OR^{10}$, —$OC(O)NR^5R^6$, —$N(R^5)C(O)NR^5R^6$, —$SO_2NR^5R^6$, —$N(R^5)SO_2R^{10}$, C_2-C_{10}alkenyl,

C_2-C_{10}alkynyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, aryl, C_1-C_6alkyl-aryl, heteroaryl and C_1-C_6alkyl-heteroaryl, wherein R^5, and R^6 are as defined in claim **1** and $R^{10}$is selected from hydrogen, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, —C(O)C_1-C_4 alkyl, —C(O)aryl, —C(O)heteroaryl, —C(O)C_3-C_6cycloalkyl, —C(O) C_3-C_6heterocycloalkyl, —$S(O)_2C_1$-C_4 alkyl, C_3-C_8cycloalkyl, C_3-C_8heterocycloalkyl, C_6-C_{14}aryl, aryl-C_1-C_{10}alkyl, heteroaryl and heteroaryl-C_1-C_{10}alkyl;

or a pharmaceutically acceptable salt thereof.

3. A compound according to claim **1** wherein:

X is O;

Y is O;

R^1 and R^4 are each independently selected from the group consisting of hydrogen, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkyl-C_1-C_{10}alkyl, C_5-C_8cycloalkenyl, C_5-C_8cycloalkenyl-C_1-C_{10}alkyl, C_3-C_8heterocycloalkyl, C_3-C_8heterocycloalkyl-C_1-C_{10}alkyl, aryl, aryl-C_1-C_{10}alkyl, heteroaryl and heteroaryl-C_1-C_{10}alkyl;

R^2 is —OR^9;

R^3 is H or C_1-C_4alkyl;

R^9 is H or a cation, or C_1-C_{10}alkyl which is unsubstituted or is substituted with one or more substituents independently selected from the group consisting of C_3-C_6 cycloalkyl, heterocycloalkyl, aryl and heteroaryl,

where any carbon or heteroatom of R^1, R^2, R^3, R^4, R^9 is unsubstituted or is substituted with one or more substituents independently selected from C_1-C_6alkyl, C_1-C_6haloalkyl, halogen, —OR^{10}, —NR^5R^6, oxo,

cyano, nitro, —C(O)R^{10}, —C(O)OR^{10}, —SR^{10}, —S(O)R^{10}, —S(O)$_2$$R^{10}$, —N$R^5$$R^6$, —CON$R^5$$R^6$, —N($R^5$)C(O)$R^{10}$, —N($R^5$)—C(O)O$R^{10}$, —OC(O)N$R^5$$R^6$, —N($R^5$)C(O)N$R^5$$R^6$, —S$O_2NR^5$$R^6$, —N($R^5$)S$O_2$$R^{10}$, C_2-C_{10} alkenyl, C_2-C_{10} alkynyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, aryl, C_1-Colkyl-aryl, heteroaryl and C_1-C_6 alkyl-heteroaryl, wherein R^5, and R^6 are the same as defined in claim **1** and $R^{10}$is selected from hydrogen, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, —C(O)C_1-C_4alkyl, —C(O)aryl, —C(O)heteroaryl, —C(O)C_3-C_6cycloalkyl, —C(O)C_3-C_6heterocycloalkyl, —S(O)$_2$$C_1$-$C_4$alkyl, C_3-C_8cycloalkyl, C_3-C_8heterocycloalkyl, C_6-C_{14}aryl, aryl-C_1-C_{10}alkyl, heteroaryl and heteroaryl-C_1-C_{10}alkyl;

or a pharmaceutically acceptable salt thereof.

4. A compound according to claim **1** wherein:

X is O;

Y is O;

R^1 and R^4 are each independently selected from the group consisting of hydrogen, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, C_3-C_8cycloalkyl, C_3-C_8cycloalkyl-C_1-C_{10}alkyl, C_5-C_8cycloalkenyl, C_5-C_8cycloalkenyl-C_1-C_{10}alkyl, C_3-C_8heterocycloalkyl, C_3-C_8heterocycloalkyl-C_1-C_{10}alkyl, aryl, aryl-C_1-C_{10}alkyl, heteroaryl and heteroaryl-C_1-C_{10}alkyl;

R^2 is —OR^9;

R^3 is H;

R^9 is H or a cation;

where any carbon or heteroatom of R^1, R^2, R^3, R^4 is unsubstituted or is substituted with one or more substituents independently selected from C_1-C_6alkyl, C_1-C_6haloalkyl, halogen, —OR^{10}, —N$R^5$$R^6$, oxo, cyano, nitro, —C(O)R^{10}, —C(O)OR^{10}, —SR^{10},

—$S(O)R^{10}$, —$S(O)_2R^{10}$, —NR^5R^6, —$CONR^5R^6$, —$N(R^5)C(O)R^{10}$, —$N(R^5)$—$C(O)OR^{10}$, —$OC(O)NR^5R^6$, —$N(R^5)C(O)NR^5R^6$, —$SO_2NR^5R^6$, —$N(R^5)SO_2R^{10}$, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, C_3-C_6cycloalkyl, C_3-C_6heterocycloalkyl, aryl, C_1-C_6alkyl-aryl, heteroaryl and C_1-C_6 alkyl-heteroaryl, wherein R^5, and R^6 are the same as defined in claim **1** and $R^{10}$is selected from hydrogen, C_1-C_{10}alkyl, C_2-C_{10}alkenyl, C_2-C_{10}alkynyl, —C(O)C_1-C_4alkyl, —C(O)aryl, —C(O)heteroaryl, —C(O)C_3-C_6cycloalkyl, —C(O)C_3-C_6heterocycloalkyl, —$S(O)_2C_1$-C_4 alkyl, C_3-C_8 cycloalkyl, C_3-C_8heterocycloalkyl, C_6-C_{14} aryl, aryl-C_1-C_{10}alkyl, heteroaryl and heteroaryl-C_1-C_{10}alkyl;

or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition which comprises a compound as described in claim **1** and one or more of pharmaceutically acceptable carriers, diluents and excipients.

6. A compound according to claim **1** which is:

N-{[1,3-bis(2,6-dichlorophenyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-({1,3-bis[(2-chlorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[(6-hydroxy-1,3-bis{[2-(methyloxy)phenyl]methyl}-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(1,3-bis{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(1-(2-biphenylyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(1-(2-bromophenyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(1-(2,4-dichlorophenyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(1-(2,6-dichlorophenyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[6-hydroxy-2,4-dioxo-1-(2-phenylethyl)-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl] carbonyl}glycine;

N-{[1-(4-chlorophenyl)-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl] carbonyl}glycine;

N-{[1-{[2,4-bis(methyloxy)phenyl]methyl}-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[1-(4-chlorophenyl)-6-hydroxy-4-oxo-3-(phenylmethyl)-2-thioxo-1,2,3,4-tetrahydro-5-pyrimidinyl] carbonyl}glycine;

N-({6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-{[6-hydroxy-2,4-dioxo-1-phenyl-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[6-hydroxy-1-(2-nitrophenyl)-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl] carbonyl}glycine;

N-{[1-[(3-cyanophenyl)methyl]-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4- tetrahydro-5-pyrimidinyl] carbonyl}glycine;

N-[(6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1-{[4-(trifluoromethyl)phenyl]methyl}-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[1-[(3,4-dichlorophenyl)methyl]-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[6-hydroxy-1-{[3-(methyloxy)phenyl]methyl}-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine; or

N-{[1-[(2,6-dichlorophenyl)methyl]-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine; or

a pharmaceutically acceptable salt thereof.

7. A compound according to claim **1** which is:

N-{[1-(1-acetyl-3-piperidinyl)-3-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl] carbonyl}glycine;

N-{[3-cyclohexyl-6-hydroxy-2,4-dioxo-1-(1-{[(phenylmethy)oxy]carbonyl}-3-piperidinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[3-cyclohexyl-6-hydroxy-2,4-dioxo-1-(3-piperidinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl] carbonyl}glycine;

N-{[3-cyclohexyl-6-hydroxy-2,4-dioxo-1-(4-piperidinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl] carbonyl}glycine;

N-({1-cyclohexyl-6-hydroxy-3-[3-(4-morpholinyl)propyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine; or

N-{[3-cyclohexyl-6-hydroxy-2,4-dioxo-1-(tetrahydro-2h-pyran-4-yl)-1,2,3,4-tetrahydro-5- pyrimidinyl] carbonyl}glycine; or

a pharmaceutically acceptable salt thereof.

8. A compound which is N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine, or a salt thereof.

9. A compound which is N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine.

10. A compound according to claim **8** which is N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine, or

a pharmaceutically acceptable salt thereof.

11. A pharmaceutical composition comprising N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

12. A compound according to claim **1** which is:

N-{[6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1-(tetrahydro-2h-pyran-4-yl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-({1-cyclohexyl-6-hydroxy-3-[(2-methylphenyl)methyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[(3-{[2-bromo-4-(1,1-dimethylethyl)phenyl]methyl}-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-({3-[(2-bromo-5-fluorophenyl)methyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[(3-{[2,4-bis(trifluoromethyl)phenyl]methyl}-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(3-{[2-bromo-5-(methyloxy)phenyl]methyl}-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-({3-(2-cyclopropylethyl)-1-[4-(2-furanyl)phenyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({3-(2-cyclopropylethyl)-6-hydroxy-1-[4-(2-methyl-1,3-thiazol-4-yl)phenyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({3-(2-cyclopropylethyl)-6-hydroxy-1-[3-(5-methyl-1,2,4-oxadiazol-3-yl)phenyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-3-{[4-(trifluoromethyl)phenyl]methyl}-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-({3-(2-cyclopropylethyl)-6-hydroxy-2,4-dioxo-1-[4-(2-thienyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-{[3-(2-cyclopropylethyl)-6-hydroxy-1-(3-nitrophenyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-({3-(2-cyclopropylethyl)-6-hydroxy-1-[4-(methyloxy)phenyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({1-cyclohexyl-3-[(3,4-difluorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({1-cyclohexyl-3-[(2,6-dichlorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({3-[(2-bromophenyl)methyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[(1-cyclohexyl-3-{[4-fluoro-2-(trifluoromethyl)phenyl]methyl}-6-hydroxy-2,4- dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-({1-cyclohexyl-3-[(3,4-difluorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({3-(2-cyclopropylethyl)-6-hydroxy-1-[3-(methyloxy)phenyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({1-cyclohexyl-3-[(3,4-dichlorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({1-cyclohexyl-3-[(2,3-difluorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({1-cyclohexyl-3-[4-(1,1-dimethylethyl)phenyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[3-cyclohexyl-6-hydroxy-1-(1-naphthalenyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-({1-cyclohexyl-3-[(2,6-dichlorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-{[1-cyclohexyl-6-hydroxy-3-(2-naphthalenyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-({1-cyclohexyl-6-hydroxy-2,4-dioxo-3-[(2,4,6-trimethylphenyl)methyl]-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({1-cyclohexyl-3-[(4-ethylphenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({1-cyclohexyl-3-[(2-ethylphenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl) glycine;

N-[(1-cyclohexyl-6-hydroxy-3-{[4-(1-methylethyl)phenyl]methyl}-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-({1-cyclohexyl-6-hydroxy-2,4-dioxo-3-[(2,4,6-trifluorophenyl)methyl]-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({1-cyclohexyl-3-[(2,4-dimethylphenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({1-cyclohexyl-6-hydroxy-2,4-dioxo-3-[(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)methyl]-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({3-[(2-chlorophenyl)methyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({1-cyclohexyl-3-[(2-fluorophenyl)methyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[(1-cyclohexyl-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[1-cyclohexyl-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl] carbonyl}glycine;

N-[(3-{[3,5-bis(methyloxy)phenyl]methyl}-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[1-cyclohexyl-6-hydroxy-3-(2-naphthalenylmethyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl] carbonyl}glycine;

N-({1-cyclohexyl-6-hydroxy-3-[(4-methylphenyl)methyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-{[3-(4-biphenylylmethyl)-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-[(3-{[4-(1,3-benzoxazol-2-yl)phenyl]methyl}-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine; or

N-({3-[2-(4-biphenylyl)-2-oxoethyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine; or

a pharmaceutically acceptable salt thereof.

13. A compound according to claim **1** which is:

N-{[3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1-(3-pyridinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4-dioxo-1-(2-thienyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1-(2-pyridinyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-[(1-(1,1-dimethylethyl)-3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-2,4- dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

n-{[3-[(2-bromophenyl)methyl]-1-(1,1-dimethylethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-{[3-{[4-(1,1-dimethylethyl)phenyl]methyl}-6-hydroxy-1-(1-methylethyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;
N-{[6-hydroxy-1-methyl-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;
N-{[1-hexyl-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;
N-{[1-ethyl-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;
N-{[6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1-propyl-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;
N-{[1-butyl-6-hydroxy-2,4-dioxo-3-(phenylmethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;
N-{[1-cyclohexyl-3-(1,1-dimethylpropyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;
N-[(1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;
N-[(1-cyclohexyl-3-hexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;
6-[5-{[(carboxymethyl)amino]carbonyl}-3-cyclohexyl-6-hydroxy-2,4-dioxo-3,4-dihydro-1(2h)-pyrimidinyl]hexanoic acid; or
6-[5-{[(carboxymethyl)amino]carbonothioyl}-3-cyclohexyl-6-hydroxy-2,4-dioxo-3,4-dihydro-1(2h)-pyrimidinyl]hexanoic acid; or
a pharmaceutically acceptable salt thereof.

14. A compound according to claim **1** which is:
N-{[1-cyclohexyl-3-(3,3-dimethyl-2-oxobutyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;
N-({3-[2-(1-benzofuran-2-yl)-2-oxoethyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-({3-[2-(4-cyanophenyl)-2-oxoethyl]-1-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;
N-({1-cyclohexyl-3[2-(4-fluorophenyl)-2-oxoethyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;
N-({1-cyclohexyl-6-hydroxy-3-[2-(4-methylphenyl)-2-oxoethyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;
N-[(1-cyclohexyl-6-hydroxy-3-{2-[4-(methyloxy)phenyl]-2-oxoethyl}-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine; or
N-{[1-cyclohexyl-6-hydroxy-2,4-dioxo-3-(2-oxo-2-phenylethyl)-1,2,3,4-tetrahydro-5-pyrimidinyl] carbonyl}glycine; or
a pharmaceutically acceptable salt thereof.

15. A compound according to claim **1** which is:
N-{[1,3-bis(2-cyclopropylethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;
N-{[3-cyclohexyl-6-hydroxy-2,4-dioxo-1-(4-phenylcyclohexyl)-1,2,3,4-tetrahydro-5-pyrimidinyl] carbonyl}glycine;
N-({1-[1,1'-bi(cyclohexyl)-4-yl]-3-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;
N-({3-cyclohexyl-6-hydroxy-1-[trans-4-(methyloxy)cyclohexyl]-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;
N-{[3-cyclohexyl-1-(4,4-dimethylcyclohexyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl] carbonyl}glycine;

3-[5-{[(carboxymethyl)amino]carbonyl}-3-cyclohexyl-4-hydroxy-2,6-dioxo-3,6-dihydro-1(2h)-pyrimidinyl]cyclohexanecarboxylic acid;

N-{[1-cyclohexyl-6-hydroxy-3-(1-methylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

cis-4-[3-cyclohexyl-5-({[2-(ethyloxy)-2-oxoethyl]amino}carbonyl)-4-hydroxy-2,6-dioxo-3,6-dihydro-1(2h)-pyrimidinyl]cyclohexanecarboxylic acid;

N-{[1-cyclohexyl-3-(4-ethylcyclohexyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

4-[5-{[(carboxymethyl)amino]carbonyl}-3-cyclohexyl-4-hydroxy-2,6-dioxo-3,6-dihydro-1(2h)-pyrimidinyl]cyclohexanecarboxylic acid;

N-{[1-cyclohexyl-3-(2,3-dimethylcyclohexyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-[(1,3-dicyclopentyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(1,3-dicycloheptyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[1-cyclohexyl-6-hydroxy-3-(2-methylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-[(3-cyclohexyl-1-cyclopentyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(1-cyclobutyl-3-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-[(3-cyclohexyl-1-cyclopropyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[1-cyclohexyl-6-hydroxy-3-(3-methylcyclohexyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;

N-({1-[(1r,2r,4s)-bicyclo[2.2.1]hept-2-yl]-3-cyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-[(3-cyclohexyl-6-hydroxy-2,4-dioxo-1-tricyclo [3.3.1.1^{3,7}]dec-1-yl-1,2,3,4-tetrahydro-5-pyrimidinyl) carbonyl]glycine;

N-[(3-cycloheptyl-1-cyclohexyl-6-hydroxy-2,4-dioxo-1, 2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;

N-{[1-cyclohexyl-3-(cyclohexylmethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl] carbonyl}glycine;

N-({1-cyclohexyl-3-[4-(1,1-dimethylethyl)cyclohexyl]-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl}carbonyl)glycine;

N-{[1-cyclohexyl-6-hydroxy-3-(4-methylcyclohexyl)-2, 4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl] carbonyl}glycine;

N-{[1-cyclohexyl-3-(2-cyclohexylethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl] carbonyl}glycine;

N-{[1-cyclohexyl-3-(2-cyclopropylethyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl] carbonyl}glycine;

ethyl n-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonothioyl]glycinate; or

N-[(1,3-dicyclohexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonothioyl]glycine; or

a pharmaceutically acceptable salt thereof.

16. A compound according to claim **1** which is:
N-{[1,3-bis(1,1-dimethylpropyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;
N-[(1,3-dibutyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;
N-{[6-hydroxy-1,3-bis(2-methylpropyl)-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;
N-{[1,3-bis(1-ethylpropyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl]carbonyl}glycine;
N-{[1,3-bis(1-ethylpropyl)-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5- pyrimidinyl]carbonyl}glycine;
N-{[6-hydroxy-2,4-dioxo-1,3-bis(1-propylbutyl)-1,2,3,4-tetrahydro-5- pyrimidinyl]carbonyl}glycine;
N-[(1,3-dihexyl-6-hydroxy-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)carbonyl]glycine;
N-{[6-hydroxy-1,3-bis(3-methylbutyl)-2,4-dioxo-1,2,3,4-tetrahydro-5- pyrimidinyl]carbonyl}glycine; or
N-{[6-hydroxy-1,3-bis(1-methylethyl)-2,4-dioxo-1,2,3,4-tetrahydro-5- pyrimidinyl]carbonyl}glycine; or
a pharmaceutically acceptable salt thereof.